PHILADELPHIA, PA – December XX, 2025 – Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company pioneering next-generation obesity and metabolic disease therapies, today announced its launch with the close of a $150 million Series A financing. The proceeds will fund Phase 1b/2 development of ALV-100 and IND-enabling work across the company’s amylin peptide and small-molecule pipeline, designed to address unmet needs in sustainable weight loss and long-term weight maintenance.
The Series A was co-led by Andera Partners, and New Rhein Healthcare Investors, with participation from Omega Funds, Sanofi, Avego Capital, and additional investors. In conjunction with the financing, [Name, Title] of Andera Partners and [Name, Title] of Omega Funds will join the Alveus Board of Directors.
“Obesity is one of the fastest-growing healthcare challenges, and current therapies face limitations around tolerability and adherence,” said Raj Kannan, Chief Executive Officer of Alveus Therapeutics. “ALV-100 is designed to achieve durable weight maintenance with infrequent dosing, offering meaningful benefits for patients. Backed by world-class investors and a team with a proven record of bringing metabolic drugs from concept to commercialization, Alveus is positioned to lead the next wave of innovation in obesity therapeutics.”
[Investor quote, e.g., Andera Partners] added, “Alveus combines a uniquely de-risked clinical asset with a leadership team that has repeatedly delivered success in this field. We’re excited to support their mission to redefine the future of obesity and metabolic disease treatment.”
“We founded Alveus to combine cutting-edge science, clinical insight, and an unwavering focus on patient outcomes to fundamentally change how the world treats obesity. With this Series A funding, we’re accelerating the development of therapies that have the potential to set a new standard of care,” said Greg Parekh, Chairman of the Board of Alveus Therapeutics
ALV-100, Alveus’s lead clinical asset, is a bifunctional GIPR antagonist and GLP-1R agonist fusion protein designed to deliver potent, durable weight loss and maintenance with improved tolerability and quarterly to semi-annual dosing.
Alveus’s amylin portfolio includes highly selective peptides, oral small molecules, and novel scaffolds designed to enhance the quality of weight loss by improving lean mass preservation and reducing nausea via AMYR3-selective mechanisms.
Leadership Team
Led by CEO Raj Kannan, former CEO of i-Mab, Aerie Pharmaceuticals, and Chiasma, Alveus brings together experts from across obesity and metabolism drug development:
Alveus Therapeutics is a clinical-stage biotechnology company developing differentiated, first- and/or best-in-class next-generation obesity and metabolic medicines designed for sustained efficacy, improved tolerability, and reduced dosing burden. The company’s lead program, ALV-100, is a GIPR antagonist mAb / GLP-1R agonist fusion protein being developed for weight loss and the simplicity of long-term weight management with infrequent dosing. Its amylin peptide and small-molecule portfolio is being developed to enhance weight-loss quality, tolerability, and lean-mass preservation. Alveus holds global rights outside Greater China, acquired from Gmax Biopharm International Limited in 2024.
For more information, visit www.alveustx.com
Media
Sasha Damouni Ellis, Damouni Group LLC
sasha@damounigroup.com
Investors
Victoria Igumnova, Meru Advisors
vigumnova@meruadvisors.com